1. Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease.
- Author
-
Croese J, Miller GC, Marquart L, Llewellyn S, Gupta R, Becker L, Clouston AD, Welch C, Sidorenko J, Wallace L, Visscher PM, Remedios ML, McCarthy JS, O'Rourke P, Radford-Smith G, Loukas A, Norrie M, Masson JW, Gearry RB, Rahman T, and Giacomin PR
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Animals, Celiac Disease immunology, Double-Blind Method, Female, Glutens administration & dosage, Glutens metabolism, Humans, Male, Middle Aged, Quality of Life, Therapy with Helminths adverse effects, Treatment Outcome, Young Adult, Celiac Disease therapy, Glutens immunology, Larva metabolism, Necator americanus metabolism, Therapy with Helminths methods
- Abstract
Introduction: Celiac disease is an autoimmune disorder where intestinal immunopathology arises after gluten consumption. Previous studies suggested that hookworm infection restores gluten tolerance; however, these studies were small (n = 12) and not placebo controlled., Methods: We undertook a randomized, placebo-controlled trial of hookworm infection in 54 people with celiac disease. The 94-week study involved treatment with either 20 or 40 Necator americanus third-stage larvae (L3-20 or L3-40) or placebo, followed by escalating gluten consumption (50 mg/d for 12 weeks, 1 g intermittent twice weekly for 12 weeks, 2 g/d sustained for 6 weeks, liberal diet for 1 year)., Results: Successful study completion rates at week 42 (primary outcome) were similar in each group (placebo: 57%, L3-20: 37%, and L3-40: 44%; P = 0.61), however gluten-related adverse events were significantly reduced in hookworm-treated participants: Median (range) adverse events/participant were as follows: placebo, 4 (1-9); L3-20, 1 (0-9); and L3-40, 0 (0-3) (P = 0.019). Duodenal villous height:crypt depth deteriorated similarly compared with their enrolment values in each group (mean change [95% confidence interval]: placebo, -0.6 [-1.3 to 0.2]; L3-20, -0.5 [-0.8 to 0.2]; and L3-40, -1.1 [-1.8 to 0.4]; P = 0.12). A retrospective analysis revealed that 9 of the 40 L3-treated participants failed to establish hookworm infections. Although week 42 completion rates were similar in hookworm-positive vs hookworm-negative participants (48% vs 44%, P = 0.43), quality of life symptom scores were lower in hookworm-positive participants after intermittent gluten challenge (mean [95% confidence interval]: 38.9 [33.9-44] vs 45.9 [39.2-52.6])., Discussion: Hookworm infection does not restore tolerance to sustained moderate consumption of gluten (2 g/d) but was associated with improved symptom scores after intermittent consumption of lower, intermittent gluten doses.
- Published
- 2020
- Full Text
- View/download PDF